
DOI . ORG {
}
Title[redir]:
Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha | Cancer Immunology, Immunotherapy
Description:
Immune responses, including natural immunity (NI), potentiate the antitumor effects of chemotherapy. Since interferons and interleukin-2 (IL-2) augment NI, a pilot study was conducted to assess the tolerability and the effects on host immunity of adjuvant chemotherapy associated with IL-2 + interferon alpha (IFN) in breast cancer patients after surgery. Ten patients underwent alternating 28-day cycles of chemoimmunotherapy [cyclophosphamide + methotrexate + 5-fluorouracil (CMF, days 1, 8) + IL-2 (days 15–19) + IFN (day 22)] and chemotherapy alone (CMF). With this regimen each patient was considered to be a reasonable “control” of herself. Blood cell count and natural killer cell activity (NKA) were tested on days 1, 8, 15, 22, and 23. Preliminary in vitro studies indicated that IL-2 or IFN antagonized the severe inhibition of NKA induced by hydroxy-peroxy-cyclophosphamide (in vitro active derivative of cyclophosphamide), alone or associated with methotrexate + 5-fluorouracil. Nine patients completed all six alternating cycles, whereas one patient proved to have metastatic lesions after four cycles. The protocol was well tolerated, although leukopenia (CMF alone) and leukopenia with fever and moderate or minimal flu-like symptoms (CMF + IL-2 + IFN) were generally observed. Treatment with IL-2 facilitated complete recovery of white cell counts and NKA after the nadir on day 15. In conclusion, the present protocol appears to be well tolerated and amenable to administration on an outpatient basis. Therefore, further investigations should be performed to verify whether CMF + IL-2 + IFN would be superior to CMF alone for adjuvant treatment after surgery in breast cancer.
Matching Content Categories {📚}
- Health & Fitness
- Science
- Telecommunications
Content Management System {📝}
What CMS is doi.org built with?
Custom-built
No common CMS systems were detected on Doi.org, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of doi.org audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Doi.org Make Money? {💸}
We don't see any clear sign of profit-making.
The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.
Keywords {🔍}
cancer, article, cmf, breast, access, privacy, cookies, content, ifn, information, publish, research, search, immunotherapy, adjuvant, treatment, interferon, alpha, chemotherapy, cell, rome, data, log, journal, immunology, pilot, study, interleukin, tonini, nunziata, prete, natural, patients, day, cycles, days, nka, open, discover, italy, springer, optional, personal, including, parties, policy, find, track, immunochemotherapy, cite,
Topics {✒️}
article cancer immunology month download article/chapter neoadjuvant anti-her2 antibodies breast cancer patients chemoimmunotherapy [cyclophosphamide + methotrexate + 5-fluorouracil breast cancer incidence il-2 + interferon alpha blood cell count white cell counts privacy choices/manage cookies full article pdf grazia graziani immunotherapy aims interferon alpha breast cancer check access instant access european economic area including natural immunity related subjects conditions privacy policy hydroxy-peroxy-cyclophosphamide vitro active derivative pilot immunochemotherapy study accepting optional cookies present protocol appears nk article tonini cell modulation journal finder publish alternating cycles article log cmf + il-2 + ifn adjuvant chemotherapy giuseppe tonini article cite methotrexate + 5-fluorouracil natural killer privacy policy personal data patients completed books a pilot study optional cookies information manage preferences rita pepponi subscription content similar content adjuvant treatment
Schema {🗺️}
WebPage:
mainEntity:
headline:Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha
description:Immune responses, including natural immunity (NI), potentiate the antitumor effects of chemotherapy. Since interferons and interleukin-2 (IL-2) augment NI, a pilot study was conducted to assess the tolerability and the effects on host immunity of adjuvant chemotherapy associated with IL-2 + interferon alpha (IFN) in breast cancer patients after surgery. Ten patients underwent alternating 28-day cycles of chemoimmunotherapy [cyclophosphamide + methotrexate + 5-fluorouracil (CMF, days 1, 8) + IL-2 (days 15–19) + IFN (day 22)] and chemotherapy alone (CMF). With this regimen each patient was considered to be a reasonable “control” of herself. Blood cell count and natural killer cell activity (NKA) were tested on days 1, 8, 15, 22, and 23. Preliminary in vitro studies indicated that IL-2 or IFN antagonized the severe inhibition of NKA induced by hydroxy-peroxy-cyclophosphamide (in vitro active derivative of cyclophosphamide), alone or associated with methotrexate + 5-fluorouracil. Nine patients completed all six alternating cycles, whereas one patient proved to have metastatic lesions after four cycles. The protocol was well tolerated, although leukopenia (CMF alone) and leukopenia with fever and moderate or minimal flu-like symptoms (CMF + IL-2 + IFN) were generally observed. Treatment with IL-2 facilitated complete recovery of white cell counts and NKA after the nadir on day 15. In conclusion, the present protocol appears to be well tolerated and amenable to administration on an outpatient basis. Therefore, further investigations should be performed to verify whether CMF + IL-2 + IFN would be superior to CMF alone for adjuvant treatment after surgery in breast cancer.
datePublished:
dateModified:
pageStart:157
pageEnd:166
sameAs:https://doi.org/10.1007/s002620050516
keywords:
Key words Interferon alpha
CMF
Breast cancer
Chemo-immunotherapy
Oncology
Immunology
Cancer Research
image:
isPartOf:
name:Cancer Immunology, Immunotherapy
issn:
1432-0851
0340-7004
volumeNumber:47
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Giuseppe Tonini
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Corrado Nunziata
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Salvatore P. Prete
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Rita Pepponi
affiliation:
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy
address:
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Mario Turriziani
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Giovanna Masci
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Grazia Graziani
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Enzo Bonmassar
affiliation:
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy
address:
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Liana De Vecchis
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha
description:Immune responses, including natural immunity (NI), potentiate the antitumor effects of chemotherapy. Since interferons and interleukin-2 (IL-2) augment NI, a pilot study was conducted to assess the tolerability and the effects on host immunity of adjuvant chemotherapy associated with IL-2 + interferon alpha (IFN) in breast cancer patients after surgery. Ten patients underwent alternating 28-day cycles of chemoimmunotherapy [cyclophosphamide + methotrexate + 5-fluorouracil (CMF, days 1, 8) + IL-2 (days 15–19) + IFN (day 22)] and chemotherapy alone (CMF). With this regimen each patient was considered to be a reasonable “control” of herself. Blood cell count and natural killer cell activity (NKA) were tested on days 1, 8, 15, 22, and 23. Preliminary in vitro studies indicated that IL-2 or IFN antagonized the severe inhibition of NKA induced by hydroxy-peroxy-cyclophosphamide (in vitro active derivative of cyclophosphamide), alone or associated with methotrexate + 5-fluorouracil. Nine patients completed all six alternating cycles, whereas one patient proved to have metastatic lesions after four cycles. The protocol was well tolerated, although leukopenia (CMF alone) and leukopenia with fever and moderate or minimal flu-like symptoms (CMF + IL-2 + IFN) were generally observed. Treatment with IL-2 facilitated complete recovery of white cell counts and NKA after the nadir on day 15. In conclusion, the present protocol appears to be well tolerated and amenable to administration on an outpatient basis. Therefore, further investigations should be performed to verify whether CMF + IL-2 + IFN would be superior to CMF alone for adjuvant treatment after surgery in breast cancer.
datePublished:
dateModified:
pageStart:157
pageEnd:166
sameAs:https://doi.org/10.1007/s002620050516
keywords:
Key words Interferon alpha
CMF
Breast cancer
Chemo-immunotherapy
Oncology
Immunology
Cancer Research
image:
isPartOf:
name:Cancer Immunology, Immunotherapy
issn:
1432-0851
0340-7004
volumeNumber:47
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Giuseppe Tonini
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Corrado Nunziata
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Salvatore P. Prete
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Rita Pepponi
affiliation:
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy
address:
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Mario Turriziani
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Giovanna Masci
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Grazia Graziani
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Enzo Bonmassar
affiliation:
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy
address:
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
name:Liana De Vecchis
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Cancer Immunology, Immunotherapy
issn:
1432-0851
0340-7004
volumeNumber:47
Organization:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy
address:
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy, , IT
type:PostalAddress
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy
address:
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy, , IT
type:PostalAddress
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Giuseppe Tonini
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Corrado Nunziata
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Salvatore P. Prete
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Rita Pepponi
affiliation:
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy
address:
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Mario Turriziani
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Giovanna Masci
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Grazia Graziani
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Enzo Bonmassar
affiliation:
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy
address:
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy, , IT
type:PostalAddress
type:Organization
name:Liana De Vecchis
affiliation:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy
address:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
name:“Istituto Dermopatico dell'Immacolata” (IDI), Rome, Italy, , IT
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
name:Institute of Experimental Medicine, National Council of Research, Rome, Italy, , IT
name:Department of Neurosciences, School of Medicine, University of Rome (Tor Vergata), Rome, Italy, , IT
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(95)
- How much profit is https://link.springer.com/privacystatement making per month?
- What is the earnings of https://link.springer.com/article/10.1007/s002620050516/#main?
- Income figures for https://link.springer.com
- How much money does https://idp.springer.com/auth/personal/springernature?redirect_uri=https://link.springer.com/article/10.1007/s002620050516 generate?
- What's the revenue for https://link.springer.com/article/10.1007/s002620050516/#eds-c-header-nav?
- What are the earnings of https://link.springer.com/journals/?
- Find out how much https://www.springernature.com/gp/authors earns monthly
- Check the income stats for https://link.springernature.com/home/
- How much revenue does https://link.springer.com/article/10.1007/s002620050516/#eds-c-header-popup-search produce monthly?
- Revenue of https://order.springer.com/public/cart
- Income figures for https://link.springer.com/article/10.1007/s002620050516/
- Discover the revenue of https://link.springer.com/article/10.1007/s002620050516/journal/262
- How much profit does https://link.springer.com/article/10.1007/s002620050516/#citeas generate?
- Revenue of https://link.springer.com/article/10.1007/s002620050516/journal/262/aims-and-scope
- Find out how much https://submission.nature.com/new-submission/262/3 earns monthly
- How much revenue does https://link.springer.com/article/10.1007/s002620050516/#auth-Giuseppe-Tonini-A1 generate?
- What's https://link.springer.com/article/10.1007/s002620050516/#A1's gross income?
- What's the monthly money flow for https://link.springer.com/article/10.1007/s002620050516/#auth-Corrado-Nunziata-A1?
- Monthly income for https://link.springer.com/article/10.1007/s002620050516/#auth-Salvatore_P_-Prete-A1
- Discover the revenue of https://link.springer.com/article/10.1007/s002620050516/#auth-Rita-Pepponi-A2
- How much money does https://link.springer.com/article/10.1007/s002620050516/#A2 make?
- What's the revenue for https://link.springer.com/article/10.1007/s002620050516/#auth-Mario-Turriziani-A1?
- How much cash flow does https://link.springer.com/article/10.1007/s002620050516/#auth-Giovanna-Masci-A1 have monthly?
- https://link.springer.com/article/10.1007/s002620050516/#auth-Grazia-Graziani-A1's financial summary
- What's the income of https://link.springer.com/article/10.1007/s002620050516/#auth-Enzo-Bonmassar-A3?
- See how much https://link.springer.com/article/10.1007/s002620050516/#A3 makes per month
- Financial intake of https://link.springer.com/article/10.1007/s002620050516/#auth-Liana-De_Vecchis-A1
- What's the income generated by https://link.springer.com/article/10.1007/s002620050516/article/10.1007/s002620050516/metrics each month?
- What's the monthly money flow for https://wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs002620050516?
- https://link.springer.com/product/springer-plus's revenue stream
- Income figures for https://www.springernature.com/gp/librarians/licensing/agc/journals
- https://link.springer.com/10.1038/s41591-024-03249-3?fromPaywallRec=true's total income per month
- How much does https://link.springer.com/10.1186/s13046-023-02918-4?fromPaywallRec=true net monthly?
- https://link.springer.com/10.1007/s11033-022-07865-5?fromPaywallRec=true's total income per month
- What's the financial outcome of https://link.springer.com/article/10.1007/s002620050516/subjects/cancer-immunotherapy?
- Learn how profitable https://link.springer.com/article/10.1007/s002620050516/subjects/chemotherapy is on a monthly basis
- How much revenue does https://link.springer.com/article/10.1007/s002620050516/subjects/immunotherapy bring in?
- How much income does https://link.springer.com/article/10.1007/s002620050516/subjects/lymphokine have?
- Learn about the earnings of https://link.springer.com/article/10.1007/s002620050516/subjects/tumour-immunology
- Financial intake of https://link.springer.com/article/10.1007/s002620050516/subjects/tumour-necrosis-factor
- How much revenue does https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Giuseppe%20Tonini generate?
- How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Giuseppe%20Tonini?
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Giuseppe%20Tonini%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Check the income stats for https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Corrado%20Nunziata
- How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Corrado%20Nunziata?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Corrado%20Nunziata%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- What's the financial gain of https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Salvatore%20P.%20Prete?
- See how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Salvatore%20P.%20Prete makes per month
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Salvatore%20P.%20Prete%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
- How much does https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Rita%20Pepponi generate monthly?
- Get to know https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rita%20Pepponi's earnings
- Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rita%20Pepponi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What's the revenue for https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Mario%20Turriziani?
- Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mario%20Turriziani
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mario%20Turriziani%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much money does https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Giovanna%20Masci make?
- Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Giovanna%20Masci earns monthly
- How much profit is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Giovanna%20Masci%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en making per month?
- How much revenue does https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Grazia%20Graziani produce monthly?
- What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Grazia%20Graziani?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Grazia%20Graziani%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- How profitable is https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Enzo%20Bonmassar?
- What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Enzo%20Bonmassar?
- How much income is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Enzo%20Bonmassar%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earning monthly?
- What's the monthly money flow for https://link.springer.com/article/10.1007/s002620050516/search?sortBy=newestFirst&dc.creator=Liana%20De%20Vecchis?
- Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Liana%20De%20Vecchis earns monthly
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Liana%20De%20Vecchis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
- https://s100.copyright.com/AppDispatchServlet?title=Adjuvant%20treatment%20of%20breast%20cancer%3A%20A%20pilot%20immunochemotherapy%20study%20with%20CMF%2C%20interleukin-2%20and%20interferon%20alpha&author=Giuseppe%20Tonini%20et%20al&contentID=10.1007%2Fs002620050516©right=Springer-Verlag%20Berlin%20Heidelberg&publication=0340-7004&publicationDate=1998-10&publisherName=SpringerNature&orderBeanReset=true income
- https://citation-needed.springer.com/v2/references/10.1007/s002620050516?format=refman&flavour=citation income
- How much income is https://link.springer.com/article/10.1007/s002620050516/search?query=Key%20words%20Interferon%20alpha&facet-discipline="Medicine%20%26%20Public%20Health" earning monthly?
- How much cash flow does https://link.springer.com/article/10.1007/s002620050516/search?query=CMF&facet-discipline="Medicine%20%26%20Public%20Health" have monthly?
- Discover the revenue of https://link.springer.com/article/10.1007/s002620050516/search?query=Breast%20cancer&facet-discipline="Medicine%20%26%20Public%20Health"
- https://link.springer.com/article/10.1007/s002620050516/search?query=Chemo-immunotherapy&facet-discipline="Medicine%20%26%20Public%20Health" income
- Get to know what's the income of https://link.springer.com/journals/a/1
- How much does https://link.springer.com/books/a/1 bring in each month?
- How much does https://link.springer.com/journals earn?
- How much money does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral make?
- What's the income of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
- Explore the financials of https://www.springernature.com/gp/products
- Earnings of https://www.springernature.com/gp/librarians
- See how much https://www.springernature.com/gp/societies makes per month
- What's the revenue for https://www.springernature.com/gp/partners?
- Learn how profitable https://www.springer.com/ is on a monthly basis
- Get to know what's the income of https://www.nature.com/
- What's the profit of https://www.biomedcentral.com/?
- Income figures for https://www.palgrave.com/
- Find out how much https://www.apress.com/ earns monthly
- What's the financial gain of https://link.springer.com/brands/discover?
- Learn about the earnings of https://www.springernature.com/gp/legal/ccpa
- https://www.springernature.com/gp/info/accessibility's financial summary
- How much does https://link.springer.com/termsandconditions pull in monthly?
- How much does https://support.springernature.com/en/support/home make?
- What are the earnings of https://link.springer.com/legal-notice?
- What's the monthly income of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
- How much does https://www.springernature.com/ make?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
Emails and Hosting {✉️}
Mail Servers:
- mx.zoho.eu
- mx2.zoho.eu
- mx3.zoho.eu
Name Servers:
- josh.ns.cloudflare.com
- zita.ns.cloudflare.com
CDN Services {📦}
- Crossref